Skip to Content

Alimta Dosage

Generic name: Pemetrexed disodium heptahydrate 100mg in 4mL
Dosage form: injection, powder, lyophilized, for solution

Medically reviewed on June 15, 2018.

Recommended Dosage for Non-Squamous NSCLC

  • The recommended dose of ALIMTA when administered with cisplatin for initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 as an intravenous infusion over 10 minutes administered prior to cisplatin on Day 1 of each 21-day cycle for up to six cycles in the absence of disease progression or unacceptable toxicity.
  • The recommended dose of ALIMTA for maintenance treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity after four cycles of platinum-based first-line chemotherapy.
  • The recommended dose of ALIMTA for treatment of recurrent NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
  • ‚ÄčThe recommended dose of ALIMTA when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Following completion of platinum-based therapy, ALIMTA may be administered as maintenance therapy, alone or with pembrolizumab, until disease progression or unacceptable toxicity. Pembrolizumab should be administered prior to ALIMTA when given on the same day. Please refer to the full prescribing information for pembrolizumab and for carboplatin.

Recommended Dosage for Mesothelioma

  • The recommended dose of ALIMTA when administered with cisplatin in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.

Renal Impairment

  • ALIMTA dosing recommendations are provided for patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater [see Dosage and Administration (2.1, 2.2)]. There is no recommended dose for patients whose creatinine clearance is less than 45 mL/min [see Use in Specific Populations (8.6)].

Premedication and Concomitant Medications to Mitigate Toxicity

Vitamin Supplementation

  • Initiate folic acid 400 mcg to 1000 mcg orally once daily, beginning 7 days before the first dose of ALIMTA and continuing until 21 days after the last dose of ALIMTA [see Warnings and Precautions (5.1)].
  • Administer vitamin B12, 1 mg intramuscularly, 1 week prior to the first dose of ALIMTA and every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with ALIMTA [see Warnings and Precautions (5.1)]. Do not substitute oral vitamin B12 for intramuscular vitamin B12.

Corticosteroids

  • Administer dexamethasone 4 mg orally twice daily for three consecutive days, beginning the day before each ALIMTA administration.

Dosage Modification of Ibuprofen in Patients with Mild to Moderate Renal Impairment Receiving ALIMTA

In patients with creatinine clearances between 45 mL/min and 79 mL/min, modify administration of ibuprofen as follows [see Warnings and Precautions (5.6), Drug Interactions (7) and Clinical Pharmacology (12.3)]:

  • Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of ALIMTA.
  • Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.

Dosage Modifications for Adverse Reactions

Obtain complete blood count on Days 1, 8, and 15 of each cycle. Assess creatinine clearance prior to each cycle. Do not administer ALIMTA if the creatinine clearance is less than 45 mL/min.

Delay initiation of the next cycle of ALIMTA until:

  • recovery of non-hematologic toxicity to Grade 0-2,
  • absolute neutrophil count (ANC) is 1500 cells/mm3 or higher, and
  • platelet count is 100,000 cells/mm3 or higher.

Upon recovery, modify the dosage of ALIMTA in the next cycle as specified in Table 1.

For dosing modifications for cisplatin, refer to the prescribing information for cisplatin.

Table 1: Recommended Dosage Modifications for Adverse Reactionsa

a National Cancer Institute Common Toxicity Criteria for Adverse Events version 2 (NCI CTCAE v2).

Toxicity in Most Recent Treatment Cycle ALIMTA Dose Modification for Next Cycle
Myelosuppressive toxicity [see Warnings and Precautions (5.1)]
ANC less than 500/mm3 and platelets greater than or equal to 50,000/mm3
OR
Platelet count less than 50,000/mm3 without bleeding.
75% of previous dose
Platelet count less than 50,000/mm3 with bleeding 50% of previous dose
Recurrent Grade 3 or 4 myelosuppression after 2 dose reductions Discontinue
Non-hematologic toxicity
Any Grade 3 or 4 toxicities EXCEPT mucositis or neurologic toxicity
OR
Diarrhea requiring hospitalization
75% of previous dose
Grade 3 or 4 mucositis 50% of previous dose
Renal toxicity [see Warnings and Precautions (5.2)] Withhold until creatinine clearance is 45 mL/min or greater
Grade 3 or 4 neurologic toxicity Permanently discontinue
Recurrent Grade 3 or 4 non-hematologic toxicity after 2 dose reductions Permanently discontinue
Severe and life-threatening Skin Toxicity [see Warnings and Precautions (5.3)] Permanently discontinue
Interstitial Pneumonitis [see Warnings and Precautions (5.4)] Permanently discontinue

Preparation for Administration

  • ALIMTA is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
  • Calculate the dose of ALIMTA and determine the number of vials needed.
  • Reconstitute ALIMTA to achieve a concentration of 25 mg/mL as follows:
    • Reconstitute each 100-mg vial with 4.2 mL of 0.9% Sodium Chloride Injection, USP (preservative-free)
    • Reconstitute each 500-mg vial with 20 mL of 0.9% Sodium Chloride Injection, USP (preservative-free)
    • Do not use calcium-containing solutions for reconstitution.
  • Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow. FURTHER DILUTION IS REQUIRED prior to administration.
  • Store reconstituted, preservative-free product under refrigerated conditions [2-8°C (36-46°F)] for no longer than 24 hours from the time of reconstitution. Discard vial after 24 hours.
  • Inspect reconstituted product visually for particulate matter and discoloration prior to further dilution. If particulate matter is observed, discard vial.
  • Withdraw the calculated dose of ALIMTA from the vial(s) and discard vial with any unused portion.
  • Further dilute ALIMTA with 0.9% Sodium Chloride Injection (preservative-free) to achieve a total volume of 100 mL for intravenous infusion.
  • Store diluted, reconstituted product under refrigerated conditions [2-8°C (36-46°F)] for no more than 24 hours from the time of reconstitution. Discard after 24 hours.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide